Key facts
- HighLife’s last known valuation is $55.5M (Jan 2019).
- It has raised $71.0M; the latest was Later Stage VC ($4.8M) in Jan 2025.
- Notable investors include Sofinnova Partners, Andera Partners, Vi Partners, Alter Domus Participations, Jose Gordo — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for HighLife
- ·The full record, as it builds
Funding rounds
No funding rounds for HighLife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HighLife
Developer of a novel transcatheter replacement system designed to help in the treatment of mitral regurgitation. The company's system targets optimal treatment outcomes as it can be delivered through a transseptal passage via the femoral vein in a reversible manner and self-locates inside the native annulus, enabling physicians to reduce trauma to the patients while carrying out severe heart surgery procedures.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2010
- Employees
- 70
- Website
- highlifemedical.com/
- Ownership
- Privately Held (backing)
HighLife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HighLife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HighLife in its N-PORT filings yet. We sweep new filings monthly.